DK3507306T3 - Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer - Google Patents

Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer

Info

Publication number
DK3507306T3
DK3507306T3 DK17765002.5T DK17765002T DK3507306T3 DK 3507306 T3 DK3507306 T3 DK 3507306T3 DK 17765002 T DK17765002 T DK 17765002T DK 3507306 T3 DK3507306 T3 DK 3507306T3
Authority
DK
Denmark
Prior art keywords
stimulatory
binding
checkpoint receptors
immunomodulatory antibodies
bispecific immunomodulatory
Prior art date
Application number
DK17765002.5T
Other languages
Danish (da)
English (en)
Inventor
Matthew Bernett
Gregory Moore
John Desjarlais
Michael Hedvat
Christine Bonzon
Umesh S Muchhal
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/623,314 external-priority patent/US10787518B2/en
Application filed by Xencor Inc filed Critical Xencor Inc
Priority claimed from PCT/US2017/049497 external-priority patent/WO2018045110A1/en
Application granted granted Critical
Publication of DK3507306T3 publication Critical patent/DK3507306T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK17765002.5T 2016-08-30 2017-08-30 Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer DK3507306T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662381239P 2016-08-30 2016-08-30
US201762456033P 2017-02-07 2017-02-07
US201762479723P 2017-03-31 2017-03-31
US15/623,314 US10787518B2 (en) 2016-06-14 2017-06-14 Bispecific checkpoint inhibitor antibodies
PCT/US2017/049497 WO2018045110A1 (en) 2016-08-30 2017-08-30 Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Publications (1)

Publication Number Publication Date
DK3507306T3 true DK3507306T3 (da) 2025-10-20

Family

ID=65632988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17765002.5T DK3507306T3 (da) 2016-08-30 2017-08-30 Bispecifikke immunmodulatoriske antistoffer, der binder co-stimulerende og checkpoint-receptorer

Country Status (12)

Country Link
EP (1) EP3507306B1 (enExample)
JP (2) JP7080219B2 (enExample)
KR (2) KR20230130174A (enExample)
CN (1) CN110267990B (enExample)
AU (1) AU2017321625A1 (enExample)
CA (1) CA3035343A1 (enExample)
DK (1) DK3507306T3 (enExample)
HR (1) HRP20251424T1 (enExample)
IL (1) IL265046B2 (enExample)
MX (1) MX2023006786A (enExample)
SG (1) SG11201901712YA (enExample)
ZA (1) ZA201901752B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3044323T3 (pl) * 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
KR102170077B1 (ko) * 2018-05-21 2020-10-27 인하대학교 산학협력단 Prss14/st14의 자가분해 고리부분을 특이적으로 인식하는 단일클론항체 및 이의 용도
MX2021005048A (es) * 2018-10-31 2021-09-08 Bioatla Inc Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
JP2023521228A (ja) * 2020-04-14 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の併用療法
WO2021209356A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2022053864A1 (en) * 2020-09-08 2022-03-17 Kwon Byoung S Pd-1 polypeptide variants
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
KR102911451B1 (ko) * 2022-05-24 2026-01-09 건국대학교 글로컬산학협력단 Rps3 결합 단클론 항체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546543B2 (en) * 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
CN103282385A (zh) * 2010-11-12 2013-09-04 美国洛克菲勒大学 用于hiv治疗的融合蛋白
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
KR102391731B1 (ko) * 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
AU2014374055B2 (en) 2013-12-30 2018-11-08 Epimab Biotherapeutics Inc. Fabs-in-tandem immunoglobulin and uses thereof
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
ES2826566T3 (es) * 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
HK1245171A1 (zh) * 2014-11-26 2018-08-24 Xencor, Inc. 结合cd3和cd38的异二聚体抗体
SMT201900702T1 (it) * 2015-01-08 2020-01-14 Genmab As Agenti agonistici leganti il recettore del tnf
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos

Also Published As

Publication number Publication date
RU2019109147A (ru) 2020-10-05
KR102575681B1 (ko) 2023-09-08
KR20190044106A (ko) 2019-04-29
CN110267990B (zh) 2023-11-07
JP2019529368A (ja) 2019-10-17
IL265046B2 (en) 2025-04-01
CA3035343A1 (en) 2018-03-08
KR20230130174A (ko) 2023-09-11
AU2017321625A1 (en) 2019-04-04
IL265046A (en) 2019-04-30
JP7080219B2 (ja) 2022-06-03
MX2023006786A (es) 2023-06-20
HRP20251424T1 (hr) 2025-12-19
SG11201901712YA (en) 2019-03-28
CN110267990A (zh) 2019-09-20
EP3507306A1 (en) 2019-07-10
JP2022111148A (ja) 2022-07-29
RU2019109147A3 (enExample) 2021-01-22
IL265046B1 (en) 2024-12-01
EP3507306B1 (en) 2025-10-01
ZA201901752B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
ZA202203250B (en) Cd3 binding antibodies
IL269531A (en) Improved antigen binding receptors
DK3223845T3 (da) Heterodimere antistoffer, der binder cd3 og cd20
IL263840A (en) Cd3 binding antibodies
DK3328889T3 (da) Bispecifikke antistofkonstruktioner, der binder dll3 og cd3
DK3328892T3 (da) Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3
IL276537A (en) Antibodies bind to GPRC5D
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
DK3665198T3 (da) Antistoffer, der binder egfr og cmet
DK3356411T3 (da) Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
DK3328893T5 (da) Bispecifikke antistofkonstruktioner, der binder mesothelin og cd3
DK3592384T3 (da) Antistoffer, der specifikt binder til human il-1r7
IL274121A (en) Bispecific antibodies that bind ALK-1 and BMPR-2
DK3328888T3 (da) ANTI-PSMA-antistoffer, bispecifikke antigenbindingsmolekyler, der binder PSMA AND og CD3, samt anvendelser deraf
DK3362477T3 (da) Antigenbindingsproteiner, der aktiverer leptinreceptoren
DK3558369T3 (da) Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
DK3097122T3 (da) Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
DK3710484T3 (da) Ctla-4-bindende antistoffer og anvendelser deraf
DK3583120T3 (da) Modificerede transferrinreceptorbindende polypeptider
DK3487882T3 (da) Anti-gprc5d-antistoffer, bispecifikke antigenbindende molekyler, der binder gprc5d og cd3, samt anvendelser deraf
DK3122781T3 (da) Bispecifikke antistoffer, der binder til cd38 og cd3
LT3247725T (lt) Anti-cd3 antikūnai, anti-cd123 antikūnai ir bispecifiniai antikūnai, specifiškai surišantys cd3 ir (arba) cd123
DK3353212T3 (da) Optimerede bispecifikke anti-CD3-antistoffer og anvendelser deraf
DK3129404T3 (da) Immunglobuliner, der binder humane vgamma9vdelta2-t-cellereceptorer